NCT03156127View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 19, 2017

Primary Completion Date

July 31, 2017

Study Completion Date

October 31, 2017

Conditions
Uterine Myoma
Interventions
DRUG

BR-UPS 5 mg tablet, Inisia 5 mg tablet

Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT03156127 - A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet | Biotech Hunter | Biotech Hunter